Co-Authors
This is a "connection" page, showing publications co-authored by Edward Levine and Reese Randle.
Connection Strength
1.192
-
Randle RW, Swords DS, Levine EA, Fino NF, Squires MH, Poultsides G, Fields RC, Bloomston M, Weber SM, Pawlik TM, Jin LX, Spolverato G, Schmidt C, Worhunsky D, Cho CS, Maithel SK, Votanopoulos KI. Optimal extent of lymphadenectomy for gastric adenocarcinoma: A 7-institution study of the U.S. gastric cancer collaborative. J Surg Oncol. 2016 Jun; 113(7):750-5.
Score: 0.137
-
Randle RW, Griffith KF, Fino NF, Swett KR, Stewart JH, Shen P, Levine EA, Votanopoulos KI. Appendiceal goblet cell carcinomatosis treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Surg Res. 2015 Jun 15; 196(2):229-34.
Score: 0.128
-
Randle RW, Ahmed S, Levine EA, Fino NF, Swett KR, Stewart JH, Shen P, Votanopoulos KI. Significance of diabetes on morbidity and mortality following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. J Surg Oncol. 2015 May; 111(6):740-5.
Score: 0.126
-
Votanopoulos KI, Russell G, Randle RW, Shen P, Stewart JH, Levine EA. Peritoneal surface disease (PSD) from appendiceal cancer treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC): overview of 481 cases. Ann Surg Oncol. 2015 Apr; 22(4):1274-9.
Score: 0.124
-
Randle RW, Doud AN, Levine EA, Clark CJ, Swett KR, Shen P, Stewart JH, Votanopoulos KI. Peritoneal surface disease with synchronous hepatic involvement treated with Cytoreductive Surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol. 2015 May; 22(5):1634-8.
Score: 0.123
-
Randle RW, Levine EA, Clark CJ, Stewart JH, Shen P, Votanopoulos KI. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for gallbladder cancer: a retrospective review. Am Surg. 2014 Jul; 80(7):710-3.
Score: 0.122
-
Randle RW, Swett KR, Swords DS, Shen P, Stewart JH, Levine EA, Votanopoulos KI. Efficacy of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in the management of malignant ascites. Ann Surg Oncol. 2014 May; 21(5):1474-9.
Score: 0.115
-
Votanopoulos KI, Swords DS, Swett KR, Randle RW, Shen P, Stewart JH, Levine EA. Obesity and peritoneal surface disease: outcomes after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for appendiceal and colon primary tumors. Ann Surg Oncol. 2013 Nov; 20(12):3899-904.
Score: 0.113
-
Randle RW, Swett KR, Shen P, Stewart JH, Levine EA, Votanopoulos KI. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in peritoneal sarcomatosis. Am Surg. 2013 Jun; 79(6):620-4.
Score: 0.113
-
Doud AN, Randle RW, Clark CJ, Levine EA, Swett KR, Shen P, Stewart JH, Votanopoulos KI. Impact of distal pancreatectomy on outcomes of peritoneal surface disease treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2015 May; 22(5):1645-50.
Score: 0.031
-
Ahmed S, Levine EA, Randle RW, Swett KR, Shen P, Stewart JH, Votanopoulos KI. Significance of diaphragmatic resections and thoracic chemoperfusion on outcomes of peritoneal surface disease treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol. 2014 Dec; 21(13):4226-31.
Score: 0.031
-
Votanopoulos KI, Randle RW, Craven B, Swett KR, Levine EA, Shen P, Stewart JH, Mirzazadeh M. Significance of urinary tract involvement in patients treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol. 2014 Mar; 21(3):868-74.
Score: 0.029